| (USD) | Jun 2026 | Y/Y change |
|---|---|---|
| Revenue | 3.04B | — |
| Operating expense | — | — |
| Net income | 320.00M | — |
| Net profit margin | — | — |
| Earnings per share | — | — |
| EBITDA | — | — |
| Effective tax rate | — | — |
Over the past year, DGX returned +38.0% with dividends reinvested.
| Period | Total return |
|---|---|
| YTD | +42.7% |
| 1 year | +38.0% |
| 5 years | +76.2% |
| 10 years | +259.6% |
| All-time high | $244.39 (Aug 2026) |
Returns are total returns and include reinvested dividends. The all-time high is the highest monthly closing price on record.
See what $1,000 in DGX would be worth today ›Yes. Quest Diagnostics Incorporated paid 4 dividends over the past 12 months. The most recent was $0.86 per share on Jul 8, 2026. The dividend yield is 1.41%.
Quest Diagnostics Incorporated stock trades on NYSE under the ticker symbol DGX.
Quest Diagnostics Incorporated is part of the Healthcare sector.
Quest Diagnostics Incorporated has a market cap of 26.97B USD, based on the latest quote.
Quest Diagnostics Incorporated is scheduled to report earnings on Oct 20, 2026.
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
